← Back to Screener
Viking Therapeutics, Inc (VKTX)
Price$35.53
Favorite Metrics
Price vs S&P 500 (26W)-3.86%
Price vs S&P 500 (4W)-0.62%
Market Capitalization$4.12B
All Metrics
Book Value / Share (Quarterly)$5.57
P/TBV (Annual)8.45x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.43
Price vs S&P 500 (YTD)-4.08%
EPS (TTM)$-3.18
10-Day Avg Trading Volume1.93M
EPS Excl Extra (TTM)$-3.18
EPS (Annual)$-3.19
ROI (Annual)-56.28%
Cash / Share (Quarterly)$6.15
ROA (Last FY)-50.25%
EBITD / Share (TTM)$-3.49
ROE (5Y Avg)-33.61%
Cash Flow / Share (Annual)$-2.43
P/B Ratio6.44x
P/B Ratio (Quarterly)6.22x
Net Income / Employee (Annual)$-7
Net Interest Coverage (TTM)-10.12x
ROA (TTM)-45.67%
EPS Incl Extra (Annual)$-3.19
Current Ratio (Annual)9.33x
Quick Ratio (Quarterly)9.21x
3-Month Avg Trading Volume2.76M
52-Week Price Return49.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.68
52-Week High$43.15
EPS Excl Extra (Annual)$-3.19
Tangible BV CAGR (5Y)60.93%
26-Week Price Return4.89%
Quick Ratio (Annual)9.21x
13-Week Price Return2.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.33x
Enterprise Value$3,951.902
Book Value / Share Growth (5Y)10.78%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.15
3-Month Return Std Dev66.79%
Net Income / Employee (TTM)$-7
ROE (Last FY)-56.28%
Net Interest Coverage (Annual)-12.22x
EPS Basic Excl Extra (Annual)$-3.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.18
ROI (TTM)-48.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.86
Price vs S&P 500 (52W)14.06%
Year-to-Date Return0.06%
5-Day Price Return0.54%
EPS Normalized (Annual)$-3.19
ROA (5Y Avg)-30.53%
Month-to-Date Return8.17%
EBITD / Share (Annual)$-3.49
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-33.61%
LT Debt / Equity (Quarterly)0.49x
EPS Basic Excl Extra (TTM)$-3.18
P/TBV (Quarterly)3.34x
P/B Ratio (Annual)6.22x
Book Value / Share (Annual)$5.57
Price vs S&P 500 (13W)-0.36%
Beta0.79x
Revenue / Share (TTM)$0.00
ROE (TTM)-48.04%
52-Week Low$21.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.30
4.29
4.29
4.24
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VKTXViking Therapeutics, Inc | — | — | — | — | $35.53 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Viking Therapeutics is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its clinical pipeline includes VK2809 and VK0214, oral selective thyroid hormone receptor beta agonists, and VK5211, an oral selective androgen receptor modulator, each targeting unmet medical needs in hormonal conditions.